In gynecologic oncology, significant advances with improved patient outcomes have clearly and thankfully resulted from randomized clinical trials. The recent restructuring of cooperative groups and decreased funding for phase III clinical trials have unintentionally resulted in a 90% reduction of available trials and accrual in gynecologic oncology. This Commentary reviews the history of the underrepresentation of women in clinical trials, highlighting the challenges that threaten the viability of gynecologic oncology clinical research, resulting in a decreased likelihood of improving the survival of women with gynecologic cancer. We suggest an opportunity for partnering with the U.S. government and the private sector to enhance research funding opportunities while increasing advocacy efforts to reinvigorate our clinical trials platform.